Effects of Yishenjiangzhuo granules on immunity and bone metabolism in patients with stage 3-4 chronic kidney disease

被引:0
|
作者
Jing Zheng [1 ]
Yingda Lin [2 ]
Lu Huang [3 ]
Caifeng Chen [3 ]
Xuemin Zheng [3 ]
Xinhong Wu [3 ]
Ciyun Liu [3 ]
机构
[1] Nephropathy Department, Fujian Provincial People's Hospital
[2] Teaching and Research Section of Internal Medicine, Fujian Provincial People's Hospital
[3] Postgraduate Department, Integration of Traditonal Chinese and Western Medicine, Fujian University of Traditional Chinese Medicine
关键词
B lymphocytes; T-lymphocytes; regulatory; Osteocalcin; Acid phosphatase; Yishenjiangzhuo granules;
D O I
暂无
中图分类号
R692 [肾疾病];
学科分类号
摘要
OBJECTIVE:To determine the effects of Yishenjiangzhuo granules(YJG)on bone metabolism and to explore the changes in levels of bone Gla protein(BGP),tartrate-resistant acid phosphatase(TRAP),as well as their relationships with levels of B cells,regulatory T cells(Treg)and interleukin(IL)-17 in patients with stage 3-4 chronic kidney disease(CKD)before and after treatment.METHODS:Fifty-three stage 3-4 CKD patients were divided randomly into two groups:YJG treatment and control.Peripheral blood was taken from two groups of CKD patients and 21 healthy subjects in the normal group.The parameters determined were the levels of CD4+,CD19+,CD19+CD69+,CD19+AV,Treg(CD4+CD25+CD127lo),BGP,TRAP,IL-17,calcium,phosphate,blood urea nitrogen,serum creatinine(SCr),hemoglobin(Hb)in peripheral blood,and urinary creatinine.Calcium-phosphate products and endogenous creatinine clearance rate(CCr)were calculated according to standard protocols.RESULTS:In YJG and control groups,SCr levels were lowered(P<0.01)after treatment,whereas CCr(P<0.05)as well as Hb and albumin levels(P<0.01)were increased.The changes in levels of CCr and SCr in the YJG group were more significant.After treatment,CD19+CD69+and Treg levels in the two groups varied(P<0.01)compared with those of the normal group;the level of CD19+increased but the levels of CD4+and CD19+AV decreased(P<0.01)in both groups.Compared with the control group,the changes of CD19+and CD19+AV in the YJG group were more apparent(P<0.05).Compared with the normal group,levels of IL-17 in both groups increased significantly(P<0.01),and the difference in the control group was more significant(P<0.05).After treatment,the TRAP level increased(P<0.05),but the difference in BGP level(P>0.05)was not significant.CONCLUSION:In stage 3-4 CKD patients,B cells and IL-17 participated in the induction of osteoclast activation.YJG could also elevate the level of B cells and decrease their apoptosis,but showed no significant effects on active B cells,IL-17 or osteoclast activity.
引用
收藏
页码:620 / 625
页数:6
相关论文
共 50 条
  • [31] Short-term efficacy of sevelamer versus calcium acetate in patients with chronic kidney disease stage 3-4
    Gulati, Ashima
    Sridhar, Vijesh
    Bose, Tathagata
    Hari, Pankaj
    Bagga, Arvind
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2010, 42 (04) : 1055 - 1062
  • [32] Predictors of mortality in patients with chronic kidney disease stages 3-4 without heart disease
    Ostlund, Ylva
    Guron, Gregor
    Saeed, Aso
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [33] Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease
    Hill, Kathleen M.
    Martin, Berdine R.
    Wastney, Meryl E.
    McCabe, George P.
    Moe, Sharon M.
    Weaver, Connie M.
    Peacock, Munro
    KIDNEY INTERNATIONAL, 2013, 83 (05) : 959 - 966
  • [34] DIURETIC MANAGEMENT OF PATIENTS WITH STAGE 3 AND 4 CHRONIC KIDNEY DISEASE
    Schulte, S.
    Daratha, K. B.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2014, 62 (01) : 237 - 237
  • [35] Effect of Exercise Training on Immune Dysfunction in Patients with Stage 3-4 Hypertensive Kidney Disease
    Bronas, Ulf G.
    Fritschi, Cynthia
    Treat-Jacobson, Diane
    Duprez, Daniel
    VASCULAR MEDICINE, 2016, 21 (03) : 305 - 305
  • [36] Vitamin D does not improve the metabolic health of patients with chronic kidney disease stage 3-4: A randomized controlled trial
    Petchey, William G.
    Hickman, Ingrid J.
    Prins, Johannes B.
    Hawley, Carmel M.
    Johnson, David W.
    Isbel, Nicole M.
    NEPHROLOGY, 2013, 18 (01) : 26 - 35
  • [37] Clinical pharmacist&nephrologist, dual management of stage 3-4 pre-dialysis chronic kidney disease patients
    Belaiche, S.
    Romanet, T.
    Baudrant, M.
    Bedouch, P.
    Calop, J.
    Allenet, B.
    Zaoui, P.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2011, 33 (02) : 412 - 413
  • [38] Renal outcomes of treatment with telmisartan in patients with stage 3-4 chronic kidney disease: A prospective, randomized, controlled trial (JINNAGA)
    Kitamura, Mineaki
    Arai, Hideyuki
    Abe, Shinichi
    Ota, Yuki
    Muta, Kumiko
    Furusu, Akira
    Mukae, Hiroshi
    Kohno, Shigeru
    Nishino, Tomoya
    SAGE OPEN MEDICINE, 2020, 8
  • [39] Mineral metabolism and outcomes in chronic kidney disease stage 2-4 patients
    Chartsrisak, Kamonwan
    Vipattawat, Kotcharat
    Assanatham, Montira
    Nongnuch, Arkom
    Ingsathit, Atiporn
    Domrongkitchaiporn, Somnuek
    Sumethkul, Vasant
    Distha-Banchong, Sinee
    BMC NEPHROLOGY, 2013, 14
  • [40] Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)
    Sellares, V. Lorenzo
    Torregrosa, V.
    NEFROLOGIA, 2008, 28 : 67 - 78